Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2020-10-20 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release dated October 20, 2020, from Martello Technologies Group Inc. It provides an update on sales and market growth for their Microsoft 365 user experience monitoring solution, Gizmo. The content focuses on recent customer wins, subscription contracts, and market opportunity. There are no financial statements, detailed financial performance data, or regulatory filing references such as 10-K or interim reports. The document is a corporate announcement about business progress and sales updates rather than a formal financial report or regulatory filing. It is not a call transcript, management report, or investor presentation, but rather a news release about company growth and product adoption. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2020-10-20 English
News release - English.pdf
Regulatory Filings
2020-10-15 English
News release - English.pdf
Regulatory Filings
2020-10-13 English
Filing statement - English.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'FORM 2A LISTING STATEMENT' and contains a detailed prospectus for Newscope Capital Corporation dated October 1, 2020. It includes extensive disclosures required by the Canadian Securities Exchange for listing, such as corporate structure, business description, financial information, capitalization, securities description, directors and officers, executive compensation, legal proceedings, and risk factors. The document is a comprehensive filing related to the company's securities offering and listing on the exchange, which aligns with a Listing Statement or Prospectus. This type of document is not an annual report, earnings release, or management discussion but rather a regulatory filing related to capital markets and securities issuance. Given the specific nature of the document as a Listing Statement and Prospectus, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes prospectuses and listing statements.
2020-10-09 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the listing of Pharmather's common shares on the Canadian Securities Exchange (CSE). It includes forward-looking statements and company background information but does not contain financial statements, detailed financial performance data, or regulatory filings. It is an announcement about a capital market event (listing on an exchange), which fits best under Capital/Financing Update (CAP). The document length is about 5,065 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or regulatory filing. There is no indication that this is a report publication announcement or a regulatory filing. Therefore, the classification is Capital/Financing Update (CAP) with high confidence.
2020-10-08 English
Final Receipt.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Draganfly Inc. has been selected as the sole provider of certain equipment for commercial production. It discusses a business partnership and product deployment but does not contain any financial data, regulatory filing references, voting results, or report announcements. The length is 4157 characters, which is relatively short and the content is clearly a business update or announcement rather than a financial report or regulatory filing. There is no indication of an annual report, earnings release, management discussion, or any other formal filing type. Therefore, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2020-10-01 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.